Listen to the management talk over the presentation here ... https://www.equitydevelopment.co.uk/webinars/?d=%3D%3DQNzUjM
Roger Bullen, Chief Executive and Hugh Cox, Founder explained the history and leading capabilities of RDT whose technology allows some of the most recognised companies in the world to best use their massive quantities of data to enhance their profitability.Click here for the full presentation ... https://www.equitydevelopment.co.uk/webinars/?d=%3D%3DQNzUjM
Equity Development held an Investor Forum on the 30th of January.
Suresh Withana, Managing Partner of Harmony Capital their investment manager, updated us on the unique offering that ADAM affords to AIM investors, progress of their investments and the ambitions of the company moving forward.
Following Benchmark's 2018 full year results we interviewed? Malcolm Pye CEO, Alex Raeber CSO and Mark Plampin FD on the progress made and the group's prospects.
Watch the full interview here ... https://www.equitydevelopment.co.uk/webinars/?d=%3D%3DwMzUjM
Following Watkin Jones' FY2019 results, new CEO Richard Simpson discusses the macro picture for both student accommodation and Build-to-Rent. Group Finance Director Phil Byrom outlines the strong on-going appetite from institutional investors for these investment classes.
Watch the full interview here ... https://www.equitydevelopment.co.uk/company/?company=Watkin+Jones&c=yUTO
Oldham Site Visit 7th February 2019
Equity development are organising a site visit to UP Global Sourcing for private investors on Thursday 7th February 2019. There will be an opportunity to look round their Oldham showroom and speak with Andrew Gossage, Managing Director, and Graham Screawn, Finance Director.
The schedule for the day would be as follows:
11am Arrive at UPGS offices
11.10 tour of the Showroom and offices
12.45 Q&A session
14.00 Visit finishes
Address: Manor Mill, Victoria Street, Chadderton, Oldham OL9 0DD
If you are interested in joining us, please email email@example.com
Kind regards, Hannah
Interview with the CEO and CFO on interims and outlook;
Following Benchmarks's 2018 interim results,we interviewed Malcolm Pye, CEO, and Mark Plampin, CFO on the progress made in the last six months and prospects for the full year.
Watch the full interview here ... https://www.equitydevelopment.co.uk/company/?company=Benchmark+Holdings&c=wETO
There is nothing wrong with banking a few profits after a parabolic move, especially when a stock becomes disproportionately large within one’s portfolio. Yet for Elektron, based purely on the fundamentals, we believe this would be a mistake despite the stock’s >5-fold rise since the 2017 lows.
Indeed, this morning the company said that Bulgin was continuing to experience buoyant demand, with YTD performance ahead of plan. Supported by a ‘record orderbook’, driving H1 expected sales up at least 8% LFL to £13.5m (LY £12.5m).
Accordingly, we have increased our FY19 turnover and EBIT forecasts for the division to £27.5m (vs £27.3 LY) and £6.9m (£7.2m) respectively. Elsewhere, EET is making good progress too, and tracking full year estimates. While Checkit is in “advanced discussions” with several global businesses to adopt its disruptive technology.
From a macro risk perspective, we understand Elektron has minimal exposure to the recently proposed ‘US-EU/Chinese’ trade tariffs, even though c.64% of revenues are generated outside the UK. Instead there may actually be a small positive forex benefit given $ appreciation vs the £ (6%) and Tunisian Dinar (10%) over the past 2 months.
So what does this all mean? Well, in terms of the group our FY19 EBIT climbs from £2.0m to £2.3m – which in turn pushes the sum-of-the-parts (SOTP) valuation 2p higher to 62p/share.
Read full article here ...https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DQNzQjM
Broadening of medical testing service
ClearStar (CLSU) is a leading technology provider to the multi $billion job screening (63% of $17.8m 2017 revenues, up 11% LFL) and drug/medical testing (37%) markets.
Momentum seems to be building. At the 22nd May trading update, CLSU announced that it had secured new work with the likes of Gulfstream Aerospace, Hilmar Cheese and BNSF Railway Company (a Berkshire Hathaway company).
Then today came news that the firm had enhanced its medical services platform by integrating the ClearMD mobile drug testing solution with Abbott Laboratories, a leading global provider of healthcare diagnostics.This immediately increases the number of CLSU locations [to >9,500] where an employee/candidate can utilise ClearMD, particularly in rural areas. What’s more the agreement should also generate significant economies of scale (eg procurement), along with speeding up the whole service proposition.
CEO Robert Vale stating: 'We are very proud to have achieved this integration with Abbott Laboratories, which makes ClearStar the only provider of paperless medical testing with a fully customisable user platform that is integrated with all three major US labs'.
Although this agreement does not change our numbers or 95p/share valuation, we nevertheless believe the stock is significantly undervalued. Underpinned by CLSU’s technological expertise, ongoing buoyant demand, high repeat revenues and 90%+ retention rates.
Read full article here... https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DgNzQjM
After three years of super-charged growth in assets under management (AUM) – from £2.8bn to £11.0bn at the end of March 2018 – there are few signs of any slowdown. Impax grew AUM by c £1bn in the first half, all organic and has already added another £0.8bn in the first two months of H2.
The Pax acquisition (now Impax Asset Management LLC) completed in January was the main event in H1. The group expects to see material benefits from reciprocal cross sales over the next two to three years. Short-term synergies may be derived from shared research and investment strategies, and integration of back/middle offices. Two independent investment teams already share research and analytical information.
Read full article here ... https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DANzQjM
Interview with CEO post results
CEO Ian Simm discusses the recent interim results and exciting outlook for Impax AM.
Watch the full interview here - https://www.equitydevelopment.co.uk/company/?company=Impax+Asset+Management&c=4QTO
We will be hosting a results webinar with the management of Benchmark Holdings.
The presentation will last around 30mins with time afterwards for Q&A. If you would like to send questions in ahead of the webinar please send them to firstname.lastname@example.org
To register for free and find out more please visit: https://attendee.gotowebinar.com/register/797626565017935027
If you would like to hear Paul Clegg, CEO, present on behalf of Accsys he will be at our next investor forum on the evening of Wednesday 21st June. Other companies also presenting are Lombard Risk Management and Carclo.
In order to find out more and to register for free please visit: https://www.eventbrite.co.uk/e/equity-development-investor-forum-june-2017-tickets-34745006249?ref=ebtn
We will be hosting a results webinar with the management of Lombard Risk on Thursday 25th May at 1.15pm.
To register please visit: https://register.gotowebinar.com/register/1039064159739962113
If you would like to send questions before the webinar please email them to email@example.com
We will be hosting an interim results webinar for Impax Asset Management Group. Ian Simm, Chief Executive, and Charlie Ridge, Chief Financial Officer, will give a presentation lasting approximately 30 mins and there will then be an opportunity for Q&A. If you would like to join please register now at:
After registering, you will receive a confirmation email containing information about joining the webinar.
If you would like to submit any questions for management ahead of the webinar please send them to firstname.lastname@example.org
If you would like to hear management present the interim results for Gattaca we will be hosting a webinar on Friday 21st of April at 1.15pm.
The registration link is: https://attendee.gotowebinar.com/register/7808442790992508675
The webinar will be a 30 minute presentation followed by q&a. If you have any questions you would like asked please send them to email@example.com
If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at 1:45pm. The presentation will last approximately 30 mins and there will then be an opportunity for Q&A.
To join please register at: https://attendee.gotowebinar.com/register/5654169658073966851
If you would like to submit any questions for management ahead of the meeting please send them to firstname.lastname@example.org
The Equity Development Team
If you would like to hear Steve Crossley, Chief Executive Officer, present on behalf of Accrol he will be appearing at our next investor forum on the evening of Wednesday 29th of March. Also appearing will be the management of Watkin Jones and Molins.
To learn more about the forum and to register for free please follow this link: https://www.eventbrite.co.uk/e/equity-development-investor-forum-march-2017-tickets-32226603639
The Equity Development team